Jubilant Pharmova Q3FY26 results show 17% revenue growth to ₹2,123 crore, driven by CDMO Sterile Injectables and improving segment performance.
Read MoreRadiopharmaceuticals
Jubilant Pharmova Q2FY26: Revenue Rises 12 Per Cent YoY, PAT Up 21 Per Cent
Jubilant Pharmova Q2FY26 results show 12% revenue growth and 21% PAT rise, driven by strong CDMO, Radiopharma, and Allergy Immunotherapy performance.
Read More